

Citations within Symposium Materials

1. Ryan, P.B., et al. *Performance of Screening Multiple Observational Databases for Active Drug Safety Surveillance*. in *International Society of Pharmacoepidemiology*. 2009. Providence, RI, USA.
2. Ryan, P.B. and G.E. Powell, *Exploring candidate differences between drug cohorts prior to exposure: A systematic approach using multiple observational databases*. *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research*, 2008. **11**(3): p. A173.
3. Whitaker, H.J., M.N. Hocine, and C.P. Farrington, *The methodology of self-controlled case series studies*. *Stat Methods Med Res*, 2009. **18**(1): p. 7-26.
4. Whitaker, H.J., et al., *Tutorial in biostatistics: the self-controlled case series method*. *Stat Med*, 2006. **25**(10): p. 1768-97.
5. Madigan, D., et al., *Bayesian Methods in Pharmacovigilance*. In , *Bayesian Statistics 9*. 2011: Oxford Scholarship Online.
6. Maclure, M., et al., *When should case-only designs be used for safety monitoring of medical products?* *Pharmacoepidemiol Drug Saf*, 2012. **21 Suppl 1**: p. 50-61.
7. Harpaz, R., et al., *Novel Data-Mining Methodologies for Adverse Drug Event Discovery and Analysis*. *Clin Pharmacol Ther*, 2012.
8. Gagne, J.J., et al., *Design considerations in an active medical product safety monitoring system*. *Pharmacoepidemiol Drug Saf*, 2012. **21 Suppl 1**: p. 32-40.
9. Rosenberg, L., P.F. Coogan, and J.R. Palmer, *Case-Control Surveillance*, in *Pharmacoepidemiology*. 2007, John Wiley & Sons, Ltd. p. 185-202.
10. Strom, B.L., *Study Designs Available for Pharmacoepidemiology Studies*, in *Pharmacoepidemiology*. 2007, John Wiley & Sons, Ltd. p. 17-28.
11. Woodward, M., *Epidemiology Study Design and Data Analysis*. 1999: Chapman & Hall/CRC.
12. Noren, N., et al., *Temporal pattern discovery for trends and transient effects: its application to patient records*, in *Proceedings of the 14th ACM SIGKDD international conference on Knowledge discovery and data mining 2008*, ACM: Las Vegas, Nevada, USA. p. 963-971.
13. Noren, N., et al., *Temporal pattern discovery in longitudinal electronic patient records*. *Data Min. Knowl. Discov.*, 2010. **20**(3): p. 361-387.
14. Noren, G.N., et al., *Safety surveillance of longitudinal databases: results on real-world data*. *Pharmacoepidemiol Drug Saf*, 2012. **21**(6): p. 673-5.
15. Noren, G.N., et al., *Safety surveillance of longitudinal databases: methodological considerations*. *Pharmacoepidemiol Drug Saf*, 2011. **20**(7): p. 714-7.
16. Schneeweiss, S., et al., *High-dimensional propensity score adjustment in studies of treatment effects using health care claims data*. *Epidemiology*, 2009. **20**(4): p. 512-22.
17. Schneeweiss, S., *A basic study design for expedited safety signal evaluation based on electronic healthcare data*. *Pharmacoepidemiol Drug Saf*, 2010. **19**(8): p. 858-68.
18. Ray, W.A., *Evaluating medication effects outside of clinical trials: new-user designs*. *Am J Epidemiol*, 2003. **158**(9): p. 915-20.
19. Sturmer, T., et al., *Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study*. *Am J Epidemiol*, 2010. **172**(7): p. 843-54.
20. Brookhart, M.A., et al., *Variable selection for propensity score models*. *Am J Epidemiol*, 2006. **163**(12): p. 1149-56.
21. Le, H.V., et al., *Performance of a semi-automated approach for risk estimation using a common data model for longitudinal healthcare databases*. *Stat Methods Med Res*, 2011.
22. Hochberg, A.M., et al., *An evaluation of three signal-detection algorithms using a highly inclusive reference event database*. *Drug Saf*, 2009. **32**(6): p. 509-25.
23. Curtis, J.R., et al., *Adaptation of Bayesian data mining algorithms to longitudinal claims data: coxib safety as an example*. *Med Care*, 2008. **46**(9): p. 969-75.
24. Almenoff, J.S., et al., *Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting*. *Pharmacoepidemiol Drug Saf*, 2003. **12**(6): p. 517-21.
25. Zorych, I., et al., *Disproportionality methods for pharmacovigilance in longitudinal observational databases*. *Stat Methods Med Res*, 2011.
26. Schuemie, M.J., *Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD*. *Pharmacoepidemiol Drug Saf*, 2011. **20**(3): p. 292-9.

Citations within Symposium Materials

27. Schuemie, M.J., *Safety surveillance of longitudinal databases: further methodological considerations.* Pharmacoepidemiol Drug Saf, 2012. **21**(6): p. 670-2.
28. Trifiro, G., et al., *EU-ADR healthcare database network vs. spontaneous reporting system database: preliminary comparison of signal detection.* Stud Health Technol Inform, 2011. **166**: p. 25-30.
29. Tata, L.J., et al., *Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?* Aliment Pharmacol Ther, 2005. **22**(3): p. 175-81.
30. Smith, B.M., et al., *Adverse events associated with treatment of latent tuberculosis in the general population.* CMAJ, 2011. **183**(3): p. E173-9.
31. Griffin, M.R., A. Yared, and W.A. Ray, *Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons.* Am J Epidemiol, 2000. **151**(5): p. 488-96.
32. Opatrny, L., J.A. Delaney, and S. Suissa, *Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look.* Br J Clin Pharmacol, 2008. **66**(1): p. 76-81.
33. Fischer, M.A., et al., *The hepatotoxicity of antifungal medications in bone marrow transplant recipients.* Clin Infect Dis, 2005. **41**(3): p. 301-7.
34. Trifiro, G., et al., *Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor?* Pharmacoepidemiol Drug Saf, 2009. **18**(12): p. 1176-84.
35. Tisdale, J. and D. Miller, *Drug-Induced Diseases: Prevention, Detection, and Management, 2nd edition.* 2010: American Society of Health-System Pharmacists.
36. Armstrong, B., *A simple estimator of minimum detectable relative risk, sample size, or power in cohort studies.* Am J Epidemiol, 1987. **126**(2): p. 356-8.
37. Schneider, V., et al., *Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis.* Am J Epidemiol, 2006. **164**(9): p. 881-9.
38. Huerta, C., et al., *Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population.* Am J Kidney Dis, 2005. **45**(3): p. 531-9.
39. Winkelmayr, W.C., et al., *Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury.* Am J Med, 2008. **121**(12): p. 1092-8.
40. Murray, M.D., et al., *Ibuprofen-associated renal impairment in a large general internal medicine practice.* Am J Med Sci, 1990. **299**(4): p. 222-9.
41. Hung, C.C., et al., *Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis.* Am J Nephrol, 2009. **29**(6): p. 633-8.
42. Sabate, M., et al., *Risk of acute liver injury associated with the use of drugs: a multicentre population survey.* Aliment Pharmacol Ther, 2007. **25**(12): p. 1401-9.
43. de Abajo, F.J., et al., *Acute and clinically relevant drug-induced liver injury: a population based case-control study.* Br J Clin Pharmacol, 2004. **58**(1): p. 71-80.
44. Garcia Rodriguez, L.A., et al., *A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs.* Br J Clin Pharmacol, 1999. **48**(6): p. 847-52.
45. Carson, J.L., et al., *Acute Liver Disease Associated with Erythromycins, Sulfonamides, and Tetracyclines.* Ann Intern Med, 1993. **119**(1): p. 576-583.
46. Ouyang, D.W., et al., *Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure.* AIDS, 2009. **23**(18): p. 2425-30.
47. Bruno, S., et al., *Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial.* BMJ, 2005. **330**(7497): p. 932.
48. Solomon, D.H., et al., *Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: High-risk subgroups and time course of risk.* Arthritis & Rheumatism, 2006. **54**(5): p. 1378-1389.
49. Helin-Salmivaara, A., et al., *NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland.* Eur Heart J, 2006. **27**(14): p. 1657-63.
50. Khader, Y.S., et al., *Oral contraceptives use and the risk of myocardial infarction: a meta-analysis.* Contraception, 2003. **68**(1): p. 11-7.
51. Mangoni, A.A., et al., *Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community.* Br J Clin Pharmacol, 2010. **69**(6): p. 689-700.

Citations within Symposium Materials

52. Warner, J.J., et al., *The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor*. J Cardiovasc Pharmacol Ther, 2008. **13**(4): p. 252-60.
53. Varas-Lorenzo, C., et al., *The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada*. Pharmacoepidemiol Drug Saf, 2009. **18**(11): p. 1016-25.
54. Roumie, C.L., et al., *Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease*. Pharmacoepidemiol Drug Saf, 2009. **18**(11): p. 1053-63.
55. Dalton, S.O., et al., *Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study*. Arch Intern Med, 2003. **163**(1): p. 59-64.
56. de Abajo, F.J. and L.A. Garcia-Rodriguez, *Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents*. Arch Gen Psychiatry, 2008. **65**(7): p. 795-803.
57. de Abajo, F.J., L.A. Rodriguez, and D. Montero, *Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study*. BMJ, 1999. **319**(7217): p. 1106-9.
58. Helin-Salmivaara, A., et al., *Risk of serious upper gastrointestinal events with concurrent use of NSAIDs and SSRIs: a case-control study in the general population*. Eur J Clin Pharmacol, 2007. **63**(4): p. 403-8.
59. Lewis, J.D., et al., *Moderate and high affinity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity*. Pharmacoepidemiol Drug Saf, 2008. **17**(4): p. 328-35.
60. Loke, Y.K., A.N. Trivedi, and S. Singh, *Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs*. Aliment Pharmacol Ther, 2008. **27**(1): p. 31-40.
61. Targownik, L.E., et al., *Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding*. Am J Gastroenterol, 2009. **104**(6): p. 1475-82.
62. Vidal, X., et al., *Risk of upper gastrointestinal bleeding and the degree of serotonin reuptake inhibition by antidepressants: a case-control study*. Drug Saf, 2008. **31**(2): p. 159-68.
63. Wessinger, S., et al., *Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis*. Aliment Pharmacol Ther, 2006. **23**(7): p. 937-44.
64. Ashworth, N.L., et al., *Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study*. J Rheumatol, 2005. **32**(11): p. 2212-7.
65. Garcia Rodriguez, L.A. and S. Hernandez-Diaz, *Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs*. Epidemiology, 2001. **12**(5): p. 570-6.
66. de Abajo, F.J. and L.A. Garcia Rodriguez, *Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations*. BMC Clin Pharmacol, 2001. **1**: p. 1.
67. Garcia Rodriguez, L.A. and L. Barreales Tolosa, *Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population*. Gastroenterology, 2007. **132**(2): p. 498-506.
68. Grimaldi-Bensouda, L., et al., *Clinical features and risk factors for upper gastrointestinal bleeding in children: a case-crossover study*. Eur J Clin Pharmacol, 2010. **66**(8): p. 831-7.
69. Hippisley-Cox, J., C. Coupland, and R. Logan, *Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis*. BMJ, 2005. **331**(7528): p. 1310-6.
70. Lanas, A., et al., *Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations*. Gut, 2006. **55**(12): p. 1731-8.
71. Laporte, J.R., et al., *Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents*. Drug Saf, 2004. **27**(6): p. 411-20.
72. Masso Gonzalez, E.L., et al., *Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding*. Arthritis Rheum, 2010. **62**(6): p. 1592-601.
73. Mellemkjaer, L., et al., *Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark*. Br J Clin Pharmacol, 2002. **53**(2): p. 173-81.

Citations within Symposium Materials

74. Rahme, E. and H. Nedjar, *Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study*. Rheumatology (Oxford), 2007. **46**(3): p. 435-8.
75. Lanas, A., et al., *Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs*. Eur J Gastroenterol Hepatol, 2003. **15**(2): p. 173-8.
76. Levesque, L.E., J.M. Brophy, and B. Zhang, *The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults*. Ann Intern Med, 2005. **142**(7): p. 481-9.